ID: ALA3319598

Max Phase: Preclinical

Molecular Formula: C25H40FN7O6

Molecular Weight: 553.64

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCCC[C@H](NC(=O)[C@@H]1C[C@H](F)CN1C(=O)[C@H](C)NC(=O)CN=[N+]=[N-])C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1

Standard InChI:  InChI=1S/C25H40FN7O6/c1-6-7-8-17(22(36)31-18(9-14(2)3)21(35)25(5)13-39-25)30-23(37)19-10-16(26)12-33(19)24(38)15(4)29-20(34)11-28-32-27/h14-19H,6-13H2,1-5H3,(H,29,34)(H,30,37)(H,31,36)/t15-,16-,17-,18-,19-,25+/m0/s1

Standard InChI Key:  SFVASCQPUQJGPO-JTUIMZOJSA-N

Associated Targets(Human)

Proteasome subunit beta type-9 308 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 553.64Molecular Weight (Monoisotopic): 553.3024AlogP: 1.30#Rotatable Bonds: 15
Polar Surface Area: 185.97Molecular Species: ACIDHBA: 7HBD: 3
#RO5 Violations: 1HBA (Lipinski): 13HBD (Lipinski): 3#RO5 Violations (Lipinski): 2
CX Acidic pKa: -10.25CX Basic pKa: CX LogP: 0.94CX LogD: 0.83
Aromatic Rings: 0Heavy Atoms: 39QED Weighted: 0.12Np Likeness Score: 0.24

References

1. de Bruin G, Huber EM, Xin BT, van Rooden EJ, Al-Ayed K, Kim KB, Kisselev AF, Driessen C, van der Stelt M, van der Marel GA, Groll M, Overkleeft HS..  (2014)  Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.,  57  (14): [PMID:25006746] [10.1021/jm500716s]

Source